A Study To Assess The Safety And Efficacy Of SU11248 In Patients With Gastrointestinal Stromal Tumor(GIST)
NCT00075218
ABOUT THIS STUDY
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
Pfizer Clinical Trials Contact Center
1-800-718-1021
- Histologically-proven diagnosis of malignant GIST not amenable to surgery, radiation or combined modality treatment with curative intent
- Failed Gleevec treatment or intolerant to Gleevec therapy
Key
- Treatment with any chemotherapy, chemoembolization therapy, immunotherapy, or
investigational agent since the last dose of Gleevec
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
- Boston, Massachusetts
- Duarte, California
- Los Angeles, California
- Los Angeles, California
- Pasadena, California
- Santa Monica, California
- Stanford, California
- Washington, District of Columbia
- Miami, Florida
- Tampa, Florida
- Park Ridge, Illinois
- Boston, Massachusetts
- Detroit, Michigan
- Minneapolis, Minnesota
- St. Louis, Missouri
- New York, New York
- New York, New York
- New York, New York
- Durham, North Carolina
- Cleveland, Ohio
- Columbus, Ohio
- Columubs, Ohio
- Portland, Oregon
- Philadelphia, Pennsylvania
- Nashville, Tennessee
- Seattle, Washington
- Seattle, Washington
- Madison, Wisconsin
- Garran, Australian Capital Territory
- Camperdown, New South Wales
- Randwick, New South Wales
- Auchenflower, Queensland
- Ashford, South Australia
- Bedford Park, South Australia
- East Melbourne, Victoria
- Leuven,
- Toronto, Ontario
- Montreal, Quebec
- Lyon,
- Marseille,
- VILLEJUIF Cedex,
- Aviano, PN
- Candiolo, Torino
- Bologna,
- Genova,
- Milano,
- Milano,
- Milano,
- Torino,
- Groningen, Gr
- Rotterdam, ZH
- Singapore,
- Singapore,
- Singapore,
- L'Hospitalet del Llobregat, Barcelona
- Barcelona,
- Madrid,
- Lausanne,
- Sutton, Surrey
- Leeds,
- London,
- Newcastle-Upon-Tyne,
- Detroit, Michigan
- Farmington Hills, Michigan
- Creve Coeur, Missouri
- St. Louis, Missouri
- St. Peters, Missouri
- Philadelphia, Pennsylvania
- Goettingen,
- Hamburg,
- Lai Chi Kok, Kowloon
- Tuen Mun, New Territories
- Hong Kong,
- Bologna,
- Milano,
- San Giovanni Rotondo,
- Seoul,
- Seoul,
- Seoul,
- Barcelona,
- Valencia,
- Glasgow,
- Leeds,
- London,
- London,
- London,
- Manchester,
Descriptive Information | ||||
---|---|---|---|---|
Brief Title ICMJE | A Study To Assess The Safety And Efficacy Of SU11248 In Patients With Gastrointestinal Stromal Tumor(GIST) | |||
Official Title ICMJE | A Phase III, Randomized, Double-Blind, Placebo-Controlled Study Of SU011248 In The Treatment Of Patients With Imatinib Mesylate (Gleevec Tm, Glivec)-Resistant Or Intolerant Malignant Gastrointestinal Stromal Tumor | |||
Brief Summary | A study to assess the safety and efficacy of SU11248 in patients with gastrointestinal stromal tumor (GIST) whose disease has failed imatinib therapy or who were intolerant to imatinib treatment. | |||
Detailed Description | Not Provided | |||
Study Type ICMJE | Interventional | |||
Study Phase ICMJE | Phase 3 | |||
Study Design ICMJE | Allocation: Randomized Intervention Model: Crossover Assignment Masking: Double (Participant, Investigator) Primary Purpose: Treatment | |||
Condition ICMJE | Gastrointestinal Stromal Tumor | |||
Intervention ICMJE |
| |||
Study Arms ICMJE |
| |||
Publications * | Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J, McArthur G, Judson IR, Heinrich MC, Morgan JA, Desai J, Fletcher CD, George S, Bello CL, Huang X, Baum CM, Casali PG. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet. 2006 Oct 14;368(9544):1329-38. | |||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | ||||
Recruitment Information | ||||
Recruitment Status ICMJE | Completed | |||
Actual Enrollment ICMJE | 361 | |||
Original Enrollment ICMJE | Not Provided | |||
Actual Study Completion Date ICMJE | May 2008 | |||
Actual Primary Completion Date | May 2008 (Final data collection date for primary outcome measure) | |||
Eligibility Criteria ICMJE | Key Inclusion Criteria:
Key Exclusion Criteria:
| |||
Sex/Gender ICMJE |
| |||
Ages ICMJE | 18 Years and older (Adult, Older Adult) | |||
Accepts Healthy Volunteers ICMJE | No | |||
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | |||
Listed Location Countries ICMJE | Australia, Belgium, Canada, France, Italy, Netherlands, Singapore, Spain, Switzerland, United Kingdom, United States | |||
Removed Location Countries | ||||
Administrative Information | ||||
NCT Number ICMJE | NCT00075218 | |||
Other Study ID Numbers ICMJE | A6181004 | |||
Has Data Monitoring Committee | Yes | |||
U.S. FDA-regulated Product | Not Provided | |||
IPD Sharing Statement ICMJE | Not Provided | |||
Responsible Party | Director, Clinical Trial Disclosure Group, Pfizer Inc | |||
Study Sponsor ICMJE | Pfizer | |||
Collaborators ICMJE | Not Provided | |||
Investigators ICMJE |
| |||
PRS Account | Pfizer | |||
Verification Date | August 2009 | |||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |